Xtant Medical, Inc. is a U.S.-based medical device company specializing in the development, manufacturing and distribution of implantable biologic and structural allograft solutions for orthopedic and spinal surgery. The company’s core product offerings include bone graft materials, spinal implant systems, surgical instrumentation and related biologic therapies designed to support bone healing and regenerative procedures. Xtant’s platform technologies encompass cryopreserved cellular bone matrices, demineralized bone matrix products and custom-milled allograft implants, all intended to integrate with host tissue and enhance patient outcomes in spinal fusion, trauma and related therapeutic indications.
Founded through a series of strategic mergers and acquisitions involving leading allograft businesses, Xtant Medical has leveraged decades of collective expertise in tissue banking and biomaterials science. The company operates from state-of-the-art FDA-registered and ISO-certified facilities in Southern California, where it maintains stringent donor screening, tissue processing and quality assurance protocols. These processes enable Xtant to supply biologic and structural grafts that comply with rigorous safety and performance standards, supporting a broad range of surgical approaches, including minimally invasive and open procedures.
In addition to its U.S. footprint, Xtant Medical distributes products internationally through a network of partners and distributors, serving markets across Canada, Europe and select regions in Asia Pacific. This global reach allows the company to address diverse clinical practices and regulatory environments, while fostering local collaborations with hospitals, ambulatory surgery centers and physician groups. Xtant’s commercial strategy is underscored by targeted field training programs and clinical support services, ensuring that surgeons and their teams can effectively integrate Xtant’s biologic and implant systems into patient care pathways.
Under the leadership of CEO Jeffrey Spanier and a management team with deep experience in orthopedics and tissue-based therapeutics, Xtant Medical continues to invest in research and development, regulatory initiatives and production scalability. The company’s forward-looking agenda includes advancing next-generation cellular allografts, expanding its structural implant portfolio and enhancing manufacturing efficiency. By aligning scientific innovation with robust quality practices, Xtant aims to address unmet clinical needs and support its long-term growth within the global spine and orthopedic markets.
AI Generated. May Contain Errors.
Free XTNT Stock Alerts